MaxCyte, Inc. announced on January 23, 2024, Cenk Sumen, Ph.D.?s employment as chief scientific officer of the company ended. Dr. Sumen will maintain a relationship with the Company as a member of the company?s Scientific Advisory Board.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
291.1 GBX | -1.32% | -9.88% | -17.42% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.42% | 387M | |
+8.69% | 220B | |
+6.69% | 183B | |
+10.90% | 133B | |
+25.41% | 107B | |
-0.34% | 63.05B | |
+12.72% | 51.74B | |
+3.96% | 50.47B | |
+0.40% | 40.91B | |
+15.03% | 40.59B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer